Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.

about

BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.

P2860

Q37174935-A9BB9F24-1977-4E72-8C74-6C9B80AD0248 Q42247393-30927898-ED34-425C-94FA-A85B7B2595B8

P2860

Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.

Item

http://www.wikidata.org/entity/Q39105498

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Immunohistochemical detection ...... with monoclonal antibody VE1.

@en

Immunohistochemical detection ...... with monoclonal antibody VE1.

@nl

type

Item

label

Immunohistochemical detection ...... with monoclonal antibody VE1.

@en

Immunohistochemical detection ...... with monoclonal antibody VE1.

@nl

prefLabel

Immunohistochemical detection ...... with monoclonal antibody VE1.

@en

Immunohistochemical detection ...... with monoclonal antibody VE1.

@nl

P1476

Immunohistochemical detection ...... with monoclonal antibody VE1.

@en

P2093

Chuanliang Cui

http://www.w3.org/2001/XMLSchema#string

Hui Liu

http://www.w3.org/2001/XMLSchema#string

Jun Guo

http://www.w3.org/2001/XMLSchema#string

Lu Si

http://www.w3.org/2001/XMLSchema#string

Qin Feng

http://www.w3.org/2001/XMLSchema#string

Weicheng Xue

http://www.w3.org/2001/XMLSchema#string

Yan Wang

http://www.w3.org/2001/XMLSchema#string

Zhongwu Li

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Mutations of the BRAF gene in human cancer

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

Vemurafenib: the first drug approved for BRAF-mutant cancer

Detection of BRAF V600E mutation by pyrosequencing

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma

The causes and consequences of genetic heterogeneity in cancer evolution

BRAF and NRAS mutations in melanoma and melanocytic nevi.

P304

601-606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/PIN.12215

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267634435

http://www.w3.org/2001/XMLSchema#string

P698

25359093

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.

about

P2860

P2860

Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921